Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Metastatic hormone refractory prostate cancer (HRPC) presents limited therapeutic options.
• Bcl-2, a pro-survival protein, is overexpressed in HRPC, correlating with treatment resistance and disease progression.
• Understanding molecular targets like Bcl-2 is crucial for developing novel prostate cancer therapies.

Purpose of the Study:

• To evaluate the potential of Oblimersen, an antisense oligonucleotide targeting Bcl-2 mRNA, as a therapeutic agent for HRPC.
• To investigate whether Oblimersen can enhance the efficacy of existing treatments for HRPC.

Main Methods:

• Pre-clinical studies demonstrated Oblimersen's ability to inhibit Bcl-2 expression.
• Clinical trials assessed the tolerability and response rates of Oblimersen in combination with chemotherapy for various cancers.
• The study proposes randomized trials to assess Oblimersen's efficacy in HRPC.

Main Results:

• Oblimersen significantly enhanced the therapeutic effects of chemotherapy, hormone, and radiation therapy in pre-clinical models.
• Clinical trials indicated good tolerability and promising response rates when Oblimersen was combined with chemotherapy.
• Pre-clinical data suggests Oblimersen's potential to overcome treatment resistance in prostate cancer.

Conclusions:

• Oblimersen is a potent inhibitor of Bcl-2 expression with potential therapeutic benefits in HRPC.
• Further randomized clinical trials are necessary to establish Oblimersen's effectiveness in combination with docetaxel for HRPC patients.
• Targeting Bcl-2 represents a promising strategy for improving outcomes in advanced prostate cancer.